Cargando…
Breast cancer chemoprevention: beyond tamoxifen
A large number of new potential chemoprevention agents are available that target molecular abnormalities found in estrogen receptor (ER)-negative and/or ER-positive precancerous breast tissue and have side effect profiles that differ from tamoxifen. Classes of agents currently undergoing evaluation...
Autor principal: | Fabian, Carol J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC139439/ https://www.ncbi.nlm.nih.gov/pubmed/11250754 http://dx.doi.org/10.1186/bcr279 |
Ejemplares similares
-
Chemoprevention: beyond tamoxifen
por: Cuzick, J
Publicado: (2005) -
Estimating the Risks and Benefits of Tamoxifen for Prophylactic Breast Cancer Chemoprevention in Korea
por: Kim, Dong Uk, et al.
Publicado: (2012) -
Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan
por: Kondo, M, et al.
Publicado: (2009) -
Persistent Metabolic Effects of Tamoxifen: Considerations for an Experimental Tool and Clinical Breast Cancer Treatment
por: Stout, Michael B, et al.
Publicado: (2021) -
Hormonal control of p53 and chemoprevention
por: Jerry, D Joseph, et al.
Publicado: (2002)